CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · Real-Time Price · USD
48.56
+0.15 (0.31%)
At close: May 18, 2026, 4:00 PM EDT
48.21
-0.35 (-0.72%)
Pre-market: May 19, 2026, 5:50 AM EDT
CRISPR Therapeutics AG Employees
CRISPR Therapeutics AG had 393 employees as of December 31, 2024. The number of employees decreased by 14 or -3.44% compared to the previous year.
Employees
393
Change (1Y)
-14
Growth (1Y)
-3.44%
Revenue / Employee
$10,440
Profits / Employee
-$1,446,651
Market Cap
4.68B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 393 | -14 | -3.44% |
| Dec 31, 2023 | 407 | -51 | -11.14% |
| Dec 31, 2022 | 458 | -15 | -3.17% |
| Dec 31, 2021 | 473 | 63 | 15.37% |
| Dec 31, 2020 | 410 | 106 | 34.87% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,965 |
| Caris Life Sciences | 1,846 |
| Travere Therapeutics | 497 |
| Xenon Pharmaceuticals | 370 |
| Immunovant | 362 |
| Cogent Biosciences | 258 |
| CG Oncology | 142 |
| NewAmsterdam Pharma Company | 100 |
CRSP News
- 5 days ago - Crispr Therapeutics price target raised to $56 from $50 at Bernstein - TheFly
- 6 days ago - CRISPR Therapeutics AG Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 7 days ago - Crispr Therapeutics price target raised to $76 from $74 at Evercore ISI - TheFly
- 12 days ago - Crispr Therapeutics price target raised to $82 from $80 at Citi - TheFly
- 12 days ago - CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference - GlobeNewsWire
- 13 days ago - Crispr Therapeutics price target lowered to $83 from $86 at BofA - TheFly
- 14 days ago - Crispr Therapeutics reports Q1 EPS ($1.28), consensus ($1.23) - TheFly
- 14 days ago - CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results - GlobeNewsWire